Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258245 · ClinicalTrials.gov registry record · Phase 1
Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
A Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00258245: Completed Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT00258245 is a Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 5 participants, below the 770-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00258245, a Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Ascorbic acid may help arsenic trioxide work better by making cancer cells more sensitive to the drug. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Giving arsenic trioxide and ascorbic acid together with bortezomib, thalidomide, and dexamethasone may stop the growth of and kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide when given together with ascorbic acid, bortezomib, thalidomide, and dexamethasone in treating patients with relapsed or refractory multiple myeloma or plasma cell leukemia.
Conditions Studied
Interventions
- DRUG dexamethasone
- DRUG bortezomib
- DRUG thalidomide
- DRUG arsenic trioxide
- DIETARY_SUPPLEMENT ascorbic acid
Study Locations (1)
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
What the finished NCT00258245 record still lists
NCT00258245 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 770-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which dexamethasone is the first listed.
NCT00258245 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT00258245 about?
NCT00258245 is a clinical study titled "Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia". RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Ascorbic acid may help arsenic trioxide work better by making cancer cells more sensitive to th...
What is the current status of trial NCT00258245?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2005-05. Estimated completion is 2008-04.
What conditions does trial NCT00258245 study?
This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00258245?
The interventions under investigation include: dexamethasone (DRUG), bortezomib (DRUG), thalidomide (DRUG), arsenic trioxide (DRUG), ascorbic acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00258245?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00258245 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma and Plasma Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00258245's enrollment target sits among peer trials
5 26th of 26 the lowest of 26 other Multiple Myeloma and Plasma Cell Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma and Plasma Cell Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
COMPLETED · Phase 1
-
Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
COMPLETED · Phase 1
-
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
COMPLETED · Phase 1
-
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
COMPLETED · Phase 1
-
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
COMPLETED · Phase 1
-
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia